Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Asthma management has changed fundamentally over the past two decades. Central to these advances have been the further elucidation of the T2 mechanisms of airway inflammation and the use of biomarkers. In addition, epithelial cells are proving to be important contributors to inflammation by generating alarmins to initiate local lesions, as well as downstream pathways. International guidelines attest to the efficacy of inhaled corticosteroids in combination with long-acting β2-agonists for both control and as-needed treatment. Revolutionizing the approach to severe asthma, five biologics, such as mepolizumab, benralizumab, reslizumab, dupilumab and tezepelumab, have joined omalizumab, significantly contributing to the prevention of exacerbations and reducing the need for systemic corticosteroids, thus minimizing their side effects. For patients with allergic asthma, one of the most common asthma phenotypes, allergen immunotherapy can be an effective adjunctive treatment alongside pharmacological therapy. This review explores the integrated modalities for symptoms control and quality of life improvement in patients with asthma and aims to provide insight into current recommendations for therapies targeting the inflammatory pathway in allergic asthma, as well as the importance of combining allergen immunotherapy on disease progression.
Asthma management has changed fundamentally over the past two decades. Central to these advances have been the further elucidation of the T2 mechanisms of airway inflammation and the use of biomarkers. In addition, epithelial cells are proving to be important contributors to inflammation by generating alarmins to initiate local lesions, as well as downstream pathways. International guidelines attest to the efficacy of inhaled corticosteroids in combination with long-acting β2-agonists for both control and as-needed treatment. Revolutionizing the approach to severe asthma, five biologics, such as mepolizumab, benralizumab, reslizumab, dupilumab and tezepelumab, have joined omalizumab, significantly contributing to the prevention of exacerbations and reducing the need for systemic corticosteroids, thus minimizing their side effects. For patients with allergic asthma, one of the most common asthma phenotypes, allergen immunotherapy can be an effective adjunctive treatment alongside pharmacological therapy. This review explores the integrated modalities for symptoms control and quality of life improvement in patients with asthma and aims to provide insight into current recommendations for therapies targeting the inflammatory pathway in allergic asthma, as well as the importance of combining allergen immunotherapy on disease progression.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.